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Dear Editor,
We have read with great interest the paper of Sherwin
et al. on individualized dosing of amikacin based on a
population pharmacokinetic and -dynamic (PKPD) study
in 80 neonates [1]. To the very best of our knowledge, this
is the first PD study (outcome indicator sepsis) of
aminoglycosides in neonates. We fully support the clinical
need to evaluate both PK and PD of drugs, including
aminoglycosides in neonates. The recent review on
aminoglycosides in neonates in this journal hereby
illustrates that clinical pharmacologists are aware of and
interested in the specific needs and characteristics of this
patient population [2]. We are, however, intrigued by the
dosing suggestions formulated by the authors: 15 mg/kg at
36-h intervals for neonates with a postmenstrual age
(PMA)≤28 weeks, 14 mg/kg at 24-h intervals for neonates
with a PMA between 29 and 36 weeks, and 15 mg/kg at
24-h intervals for neonates with a PMA≥37 weeks [1].
Firstly, if we apply the clearance model proposed
clearance ¼ 0:23  current weight=2ð Þ0:691  PMA=40ð Þ3:23
h i
to the range of neonates included (weight 0.44−4.4 kg;
PMA 24−41 weeks), clearance ranges from 0.0155 to
0.428 L/h (30-fold interindividual variability). This exten-
sive interindividual variability in clearance is not reflected in
the dosing recommendations formulated. As aminoglycoside
clearance reflects glomerular filtration rate (GFR), it is to be
anticipated that maturational clearance displays a continuum,
instead of the dichotomous pattern: 50% reduction in
amikacin administration ≤ 28 weeks, and only a very limited
additional interindividual variability (<10%) between 29-
weeks and full-term neonates seems not to be in line with
developmental maturation of renal clearance capacity. Al-
though it is likely that the current dosing suggestions fit best
with the available data set, it is a likely that the current
suggestions do not yet fully reflect the interindividual
variability in clearance of aminoglycosides in neonates [2–4].
Secondly, based on the fact that interindividual variability
in any aminoglycoside clearance reflects interindividual
variability in GFR, we urgently call for prospective validation
of the current and other clearance models suggested. As
clearance of aminoglycoside reflects the interindividual
variability in GFR, cross-validation studies should include
not only different cohorts but also different aminoglycosides.
We hereby would like refer to the netilmicin study in neonates
recently published by the same group, where the clearance
model seems to be based on the same covariates model
netilmicin clearance ¼ 0:192  current weight=2ð½ Þ1:35 
PMA=40ð Þ1:03 but with different exponential factors [5].
Besides collaboration between different centers and
groups, such cross-validation studies necessitate robust data
sets that include other relevant covariates in addition to
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PMA or weight alone. We miss information on the
existence of a patent ductus arteriosus (PDA), on the
exposure to indomethacin or ibuprofen to induce closure of
the PDA, or on the presence of growth restriction. as it has
been clearly demonstrated that these covariates in part
explain the interindividual variability in aminoglycoside
clearance in neonates [6–8]. Similarly, we would like to
mention the relevance of the technique used to determine
creatinine level in the blood. For decades we have known
that the Jaffe method introduces additional errors when
used in neonates because of interferences by, e.g., ketoa-
cids, bilirubin, or cephalosporins. It really makes a
difference to use an enzymatic method in this age group [9].
In conclusion, we would like to encourage the authors
and other research groups interested to critically re-evaluate
their single cohort aminoglycoside clearance model and
recommendations. In addition to single population studies,
cross-validation studies, including extrapolation of a given
clearance model to data sets with other aminoglycosides,
are urgently needed to unveil the underlying maturational
GFR and its covariates. This will necessitate collaborative
efforts and can only be based on robust data sets including
covariates of potential relevance and should not be limited
to weight or PMA alone.
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